… was to report the safety and efficacy of erlotinib in the Australian patient subpopulation. …
The observed ORR for patients receiving erlotinib as first-line, second-line and third-line therapy …

… alone or intercalated with chemotherapy (CT + erlotinib) in chemotherapy-naïve patients
with advanced NSCLC who were positive for epidermal growth factor receptor (EGFR) protein …

… Of patients diagnosed with advanced lung adenocarcinoma, those with activating EGFR
mutations treated with first-line erlotinib or gefitinib generally have a high objective response …

… In this study of Chinese patients we analysed the clinical efficacy of erlotinib and measured
levels of TGF-alpha and VEGF in the plasma prior to and 1 month after oral erlotinib. …

… the difference in the efficacy of erlotinib and gefitinib in previously treated NSCLC patients. …
Among these patients, 9156 patients were prescribed erlotinib or gefitinib after first-line …

… to determine if cytoreductive SBRT plus erlotinib could prolong PFS compared with historical
findings at or beyond second-line therapy for patients with metastatic NSCLC with limited …

… erlotinib in patients with advanced EGFR-mutant NSCLC. … with different agents including
erlotinib, bevacizumab, … nivolumab combined with erlotinib in a cohort of patients with …

… Erlotinib is indicated as first-line treatment for patients with non-small-cell lung cancer (NSCLC)
harboring an epidermal growth-factor–receptor (EGFR) mutation. Addition of a vascular …

834 Background: The combination of capecitabine (C) and vinorelbine (V) is active and has
an acceptable toxicity profile in metastatic breast cancer (MBC) patients(pts) pretreated with …

… Patients in SATURN were randomized to receive either erlotinib maintenance therapy or
placebo, 2 whereas those in TITAN were randomized to receive either second-line erlotinib or …